Novo Nordisk, Eli Lilly and obesity
Digest more
Weight loss drugs are set to become a disproportionate share of Lilly's business.
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.
Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...
Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...
Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...
Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...
Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback